Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy. [electronic resource]
Producer: 20170509Description: 176-87 p. digitalISSN:- 1873-2968
- 3-Hydroxysteroid Dehydrogenases -- antagonists & inhibitors
- Activation, Metabolic -- drug effects
- Aldo-Keto Reductase Family 1 Member C3
- Animals
- Antineoplastic Agents, Alkylating -- chemistry
- Benzamides -- chemistry
- Carcinoma -- drug therapy
- Cell Proliferation -- drug effects
- Colorectal Neoplasms -- drug therapy
- Drug Design
- Drug Resistance, Neoplasm -- drug effects
- Enzyme Inhibitors -- pharmacology
- Escherichia coli Proteins -- genetics
- HCT116 Cells
- Humans
- Hydroxyprostaglandin Dehydrogenases -- antagonists & inhibitors
- Mesylates -- chemistry
- Mice, Nude
- Models, Molecular
- Molecular Docking Simulation
- Nitroreductases -- genetics
- Organophosphonates -- chemistry
- Prodrugs -- chemistry
- Random Allocation
- Recombinant Proteins -- chemistry
- Specific Pathogen-Free Organisms
- Substrate Specificity
- Survival Analysis
- Tumor Burden -- drug effects
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.